JP6290947B2 - Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin permeability - Google Patents

Description

  The present invention relates to preparations of positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids and related compounds, and non-steroidal anti-inflammatory drugs (NSAIAs) -treatable conditions in humans or animals It relates to its medicinal use. More specifically, the present invention is to overcome the side effects associated with the use of NSAIA. These prodrugs can be administered orally or transdermally.

  There are 2-aryl- and heteroarylpropionic acids, 3-aryl- and heteroarylpropionic acids and cyclized aryl-and heteroarylpropionic acids. 2- (6-methoxy-2-naphthyl) propionic acid (naproxen), α-methyl-4- (2-thienylcarbonyl) benzeneacetic acid (suprofen), α-methyl- (p-chlorobenzoyl) -5-methoxy- 2-methylindole-3-acetic acid, 2- (2-fluoro-4-biphenylyl) propionic acid (flurbiprofen), 6-chloro-α-methyl-9H-carbazole-2-acetic acid (carprofen), α- Methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetic acid (planoprofen), 2- (4-chlorophenyl) -α-methyl-5-benzoxazoleacetic acid (benoxaprofen), α-methyl-4-[(2-methyl-2-propenyl) amino] benzeneacetic acid (aluminoprofen), 5-benzoyl-α-methyl-2- Ofenacetic acid (thiaprofenic acid), 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzeneacetic acid (pyruprofen), 2- (10,11-dihydro-10-oxo Dibenzo (b, f) thiepin-2-yl) propionic acid (zaltoprofen), 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionic acid (velmopro) Phen), 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionic acid (loxoprofen), 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methyl Benzeneacetic acid (indoprofen), α, 3-dichloro-4-cyclohexylbenzeneacetic acid (fenchlorac), and related compounds are: It is one of the 2-aryl- and heteroarylpropionic acid groups of non-steroidal anti-inflammatory drugs. 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin), 3- (4-biphenylylcarbonyl) propionic acid (fenbufen), 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionic acid (olpanoxin) And related compounds are one of the 3-aryl- and heteroarylpropionic acid groups of non-steroidal anti-inflammatory drugs. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid (ketorolac), 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid (clidanac) And related compounds are one of the cyclized aryl- and heteroarylpropionic acid groups of non-steroidal anti-inflammatory drugs. They are used for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and are used for the treatment of dysmenorrhea. They are also used for the treatment of acute gout arthritis and ankylosing spondylitis. These can be used for the treatment of dementia (McGeer; Patrick L. et al. U.S. Pat. No. 5,192,753).

  Unfortunately, many side effects are naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, Associated with the use of aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds, most notably gastrointestinal disorders For example, dyspepsia, gastroduodenal bleeding, gastric ulcer, and gastritis. Fishman (Fishman; Robert, U.S. Pat. No. 7,052,715) pointed out additional challenges associated with oral drug therapy. That is, in order to effectively treat painful or inflamed ends, the concentration level that must be achieved in the bloodstream must be significant. These levels are often much higher than required when it is possible to accurately target specific sites with pain or injury. Fishman et al. (Van Engelen et al. US Pat.No. 6,416,772; Macrides et al. US Pat.No. 6,346,278; Kirby et al. US Pat.No. 6,444,234, Roentsch, et al., US Pat. 5,654,337, Park, et al., US Pat.No. 6,190,690, Pearson et al. US Pat.No. 6,528,040 and Botknecht et al. US Pat. No. 5,885,597), trying to develop a transdermal delivery system with the combination Tried. However, due to the slow skin penetration rate, it is very difficult to deliver therapeutically effective plasma levels of these types of drugs to the host by formulation. Susan Milosovich et al. Designed and prepared testosteronyl-4-dimethylaminobutyrate. HCl (TSBH). It has a lipophilic moiety and a tertiary amine group that exists in protonated form at physiological pH. They found that prodrug (TSBH) diffuses through human skin ~ 60 times faster than drug (TS) itself [Susan Milosovich, et al., J. Pharm. Sci., 82,227 (1993)].

Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, Pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds have been used medicinally for many years. They are used for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and are used for the treatment of dysmenorrhea.
Unfortunately, many side effects are associated with the use of NSAIA, most notably gastrointestinal disorders, such as dyspepsia, gastroduodenal bleeding, gastric ulcers, and gastritis. They are insoluble in aqueous solutions and gastric juices. They stay in the gastrointestinal tract for a long time and can thus cause damage to gastric mucosal cells.

  The present invention relates to the preparation of novel positively charged prodrugs of aryl- and heteroarylpropionic acids and related compounds, and their pharmaceutical uses. 2- (6-methoxy-2-naphthyl) propionic acid (naproxen), α-methyl-4- (2-thienylcarbonyl) benzeneacetic acid (suprofen), α-methyl- (p-chlorobenzoyl) -5-methoxy- 2-methylindole 3-acetic acid, 2- (2-fluoro-4-biphenylyl) propionic acid (flurbiprofen), 6-chloro-α-methyl-9H-carbazole-2-acetic acid (carprofen), α-methyl -5H- [1] benzopyrano [2,3-b] pyridine-7-acetic acid (planoprofen), 2- (4-chlorophenyl) -α-methyl-5-benzoxazoleacetic acid (benoxaprofen), α -Methyl-4-[(2-methyl-2-propenyl) amino] benzeneacetic acid (aluminoprofen), 5-benzoyl-α-methyl-2-thi Phenacetic acid (thiaprofenic acid), 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzeneacetic acid (pyruprofen), 2- (10,11-dihydro-10-oxo Dibenzo (b, f) thiepin-2-yl) propionic acid (zaltoprofen), 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionic acid (velmopro) Phen), 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionic acid (loxoprofen), 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methyl Benzeneacetic acid (indoprofen), α, 3-dichloro-4-cyclohexylbenzeneacetic acid (fenchlorac), and related compounds are: It is one of and heteroaryl acid group - steroidal antiinflammatory agents 2-aryl. Prodrugs of 2-aryl- and heteroarylpropionic acids have the structure of the following formula (1).

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、Ａｒｙｌは以下のものを表す。

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, 1 to 12 carbon atoms X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, and A ⁻ represents any one of alkyl, alkyloxy, alkenyl or alkynyl residues having Represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or anion, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. , Ary It represents the following:.

全てのＲ基はＣ、Ｈ、Ｏ、Ｓ、又はＮ原子を含んでもよく、単結合、二重結合、及び三重結合を有してもよい。ＣＨ₂基はＯ、Ｓ又はＮＨと置換されてもよい。

All R groups may contain C, H, O, S, or N atoms and may have single, double, and triple bonds. The CH ₂ group may be substituted with O, S or NH.

  4,5-diphenyl-2-oxazolepropionic acid (oxaprozin), 3- (4-biphenylylcarbonyl) propionic acid (fenbufen), 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionic acid (olpanoxin) And related compounds are one of the 3-aryl- and heteroarylpropionic acid groups of non-steroidal anti-inflammatory drugs. Prodrugs of 3-aryl- and heteroarylpropionic acids have the structure of formula (2)

式中、ＷはＨ、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、ＷはＯＨ、Ｃｌ又はＦを表し、ＹはＨ、Ｃｌ、ＯＨ、又はＣＨ₃を表し、及びＺは以下のものを表す。

In the formula, W represents H, OH, Cl, F, or Br, and R ₁ is H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms Any one of alkyl, alkyloxy, alkenyl or alkynyl residues, or an aryl residue, X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, A ⁻ represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. W is OH, represents l or F, Y represents H, Cl, OH, or CH _3, and Z represents the following.

全てのＲ、Ｒ₁、Ｒ₂、Ｒ₃、及びＲ₄基はＣ、Ｈ、Ｏ、Ｓ、Ｎ原子を含んでもよく、単結合、二重結合、及び三重結合を有してもよい。ＣＨ₂基はＯ、Ｓ又はＮＨと置換されてもよい。

All R, R ₁ , R ₂ , R ₃ , and R ₄ groups may contain C, H, O, S, N atoms and may have single, double, and triple bonds. The CH ₂ group may be substituted with O, S or NH.

環化アリール−及びヘテロアリールプロピオン酸が形成される。これらは５−ベンゾイル−２，３−ジヒドロ−１Ｈ−ピロリジン−１−カルボン酸（ケトロラク）、６−クロロ−５−シクロヘキシル−２，３−ジヒドロ−１Ｈ−インデン−１−カルボン酸（クリダナク）、及び関連化合物である。 In formula (2), when W represents H, Y and Z both represent the following.

Cyclized aryl- and heteroarylpropionic acids are formed. These are 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylic acid (ketorolac), 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid (clidanac), And related compounds.

Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (A, 30% solution), diethylaminoethyl α-methyl-permeate isolated human skin tissue in Franz cells (n = 5) 4- (2-thienylcarbonyl) benzeneacetate acetate (B, 30% solution), diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (C, 30% solution), diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate (D, 30% solution), diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate (E , 30% solution), naproxen (F, 30% suspension), suprofen (G, 30% suspension), α Methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid (H, 30% suspension), flurbiprofen (I, 30% suspension), or carprofen (J, 30 % Suspension). In each case, the medium was pH 7.4 phosphate buffer (0.2M). Diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate (A, 30) permeating isolated human skin tissue in Franz cells (n = 5) % Solution), diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate acetate (B, 30% solution), diethylaminoethyl α-methyl-4-[(2-methyl-2- Propenyl) amino] benzene acetate acetate (C, 30% solution), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate (D, 30% solution), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzeneacetate acetate (E, 30% solution), pranoprof (F, 30% suspension), Benoxaprofen (G, 30% suspension), Aluminoprofen (H, 30% suspension), Tiaprofenic acid (I, 30% suspension), Or the cumulative amount of pirprofen (J, 30% suspension). In each case, the medium was pH 7.4 phosphate buffer (0.2M). Diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate permeating isolated human skin tissue in Franz cells (n = 5) A, 30% solution), diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate (B, 30% solution), diethylaminoethyl 2 -[4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (C, 30% solution), diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl)- α-Methylbenzene acetate acetate (D, 30% solution), diethylaminoethyl α, 3-dichloro-4-cyclohexyl Benzene acetate acetate (E, 30% solution), zaltoprofen (F, 30% suspension), vermoprofen (G, 30% suspension), loxoprofen (H, 30% suspension), indopro Cumulative amount of phen (I, 30% suspension) or fenchlorac (J, 30% suspension). In each case, the medium was pH 7.4 phosphate buffer (0.2M). Diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (A, 30% solution), diethylaminoethyl 3- (4) permeating isolated human skin tissue in Franz cells (n = 5) -Biphenylylcarbonyl) propionate acetate (B, 30% solution), diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate (C, 30% solution), diethylaminoethyl 5- Benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (D, 30% solution), diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate Acetate (E, 30% solution), oxaprozin (F, 30% suspension), femb E emissions (G, 30% suspension), orpanoxin (H, 30% suspension), ketorolac (I, 30% suspension), or the cumulative amount of clidanac (J, 30% suspension). In each case, the medium was pH 7.4 phosphate buffer (0.2M). Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (A), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (B), diethylaminoethyl α- in isopropanol Methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (C), diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate (D), diethylaminoethyl 6- Chloro-α-methyl-9H-carbazole-2-acetate acetate (E), naproxen (F), suprofen (G), α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3- Acetic acid (H), flurbiprofen (I), or carprofe Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid after topical application of 1 ml of 20% solution of (J) to the back of hairless mice (n = 5) , Total plasma levels of flurbiprofen and carprofen. Diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate (A), diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoin in isopropanol Oxazole acetate acetate (B), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate (C), diethylaminoethyl 5-benzoyl-α-methyl-2- Thiophene acetate acetate (D), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate (E), pranoprofen (F ), Benoxaprofen (G), aluminoprofen (H), thiaprofenic acid (I), or pillpro E down backs after topical application of hairless mice 20% solution 1ml of (J) (n = 5), pranoprofen, benoxaprofen, alminoprofen, tiaprofenic acid, or total plasma levels of pirprofen. Diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate (A), diethylaminoethyl 2- (8-methyl-10,11-dihydro) in isopropanol 11-oxodibenz (b, f) oxepin-2-yl) propionate acetate (B), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (C), diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate (D), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate ( E), zaltoprofen (F), vermoprofen (G), loxo Zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac after topical application of 1 ml of a 20% solution of lofen (H), indoprofen (I), fenchlorac (J) to the back of hairless mice (n = 5) Total plasma levels. Diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate (A), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (B), diethylaminoethyl 5- (4-chlorophenyl) in isopropanol -Beta-hydroxy-2-furanpropionate acetate (C), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (D), diethylaminoethyl 6-chloro-5 20 of cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate (E), oxaprozin (F), fenbufen (G), olpanoxin (H), ketorolac (I), or clidanac (J) 1 ml of% solution in hairless mice (n = ) Back to after topical application, oxaprozin, fenbufen, orpanoxin, ketorolac, and total plasma levels of clidanac. Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (B), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (C), diethylaminoethyl α-methyl- ( p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (D), diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate (E), diethylaminoethyl 6-chloro-α -Pain threshold extension time of mouse tail after transdermal administration of methyl-9H-carbazole-2-acetate acetate (F) at 50 mg / kg. Group A is a control group. Diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate (G), diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate Acetate (H), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate (I), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate Acetate (J), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzeneacetate acetate (K) after 50 mg / kg transdermal administration , Mouse tail pain threshold extension time. Group A is a control group. Diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate (L), diethylaminoethyl 2- (8-methyl-10,11-dihydro-11- Oxodibenz (b, f) oxepin-2-yl) propionate acetate (M), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (N), diethylaminoethyl 4- (1, 3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzeneacetate acetate (O), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate acetate (P) Pain threshold time of mouse tail after dermal administration of 50 mg / kg. Group A is a control group. Diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (Q), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (R), diethylaminoethyl 5- (4-chlorophenyl) -beta- Hydroxy-2-furanpropionate acetate (S), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (T), diethylaminoethyl 6-chloro-5-cyclohexyl- Pain threshold extension time of mouse tail after transdermal administration of 2,3-dihydro-1H-indene-1-carboxylate acetate (U) at 50 mg / kg. Group A is a control group. Uplift rate (%) after carrageenan administration. One hour before administration of carrageenan, diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (100 mg / kg, B), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (100 mg / kg, C), diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (100 mg / kg, D), diethylaminoethyl 2- (2-fluoro -4-biphenylyl) propionate acetate (100 mg / kg, E) and diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate (100 mg / kg, F) were administered transdermally. Group A is a control group. Uplift rate (%) after carrageenan administration. One hour before administration of carrageenan, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate (100 mg / kg, G), diethylaminoethyl 2- (4-chlorophenyl) -Α-methyl-5-benzoxazole acetate acetate (100 mg / kg, H), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate (100 mg / kg I), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate (100 mg / kg, J), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrole-1- Yl) -α-methylbenzene acetate acetate (100 mg / kg, K) was transdermally administered. Group A is a control group. Uplift rate (%) after carrageenan administration. One hour before administration of carrageenan, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate (100 mg / kg, L), diethylaminoethyl 2- (8 -Methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate (100 mg / kg, M), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl ] Propionate acetate (100 mg / kg, N), diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate (100 mg / kg, O), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate acetate (100 mg / kg, P) was transdermally administered. . Group A is a control group. Uplift rate (%) after carrageenan administration. One hour before the administration of carrageenan, diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (100 mg / kg, Q), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (100 mg / kg, R), diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate (100 mg / kg, S), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1 -Carboxylate acetate (100 mg / kg, T), diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate (100 mg / kg, U) transdermally did. Group A is a control group. In Structure 1, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ is H, any one of alkyl, alkyloxyl, alkenyl, or alkynyl residues having 1 to 12 carbon atoms, or aryl Represents a residue, R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, 1 to 12 carbon atoms represents alkyl, alkyloxy, any one alkenyl or alkynyl residue, or an aryl residue having, X represents _{O, S, NH, OCH 2} COO, OCH 2 COS, or OCH ₂ CONH, a ^- Represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or an anion, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Yes, A yl aryl - represents a and heteroaryl groups. In Structure 2, W represents H, OH, Cl, F, or Br, and R ₁ is H, any one of alkyl, alkyloxyl, alkenyl, alkynyl residues having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, 1 to 12 carbon atoms X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, and A ⁻ represents any one of alkyl, alkyloxy, alkenyl or alkynyl residues having Represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or anion, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. , Y or And Z are both aryl - represents a and heteroaryl groups.

  Drug absorption requires the drug to pass across the barrier membrane in molecular form, whether from the gastrointestinal tract or from other sites. The drug must first dissolve, and if the drug has the desired biopharmaceutical properties, it passes across the membrane from a high concentration region to a low concentration region, and blood circulation or body It will go into circulation. All biological membranes contain lipids as a major constituent. The molecules that play a major role in film formation all have a phosphate-containing high polarity head group, and in most cases have two highly hydrophobic hydrocarbon tails. The membrane is a bimolecular membrane with its two hydrophilic head groups pointing outwards to the aqueous regions on both sides. Very hydrophilic drugs cannot pass through the hydrophobic layer of the membrane, and very hydrophobic drugs remain in the hydrophobic layer as part of the membrane due to their similarity, and in the inner cytosol You will not be able to enter efficiently.

  The object of the present invention is to provide naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxax in gastric juice Increase the solubility of prophene, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds, and To avoid its side effects by increasing its permeability through membranes and skin barriers, which would allow transdermal administration (topical application). These new prodrugs have two structural features in common. They have a lipophilic moiety and a primary, secondary or tertiary amine group (hydrophilic moiety) that exists in protonated form at physiological pH. Such a hydrophilic / lipophilic balance is required for efficient passage through the membrane barrier [Susan Milosovich, et al., J. Pharm. Sci., 82, 227 (1993)]. A positively charged amino group greatly increases the solubility of the drug.

  Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate.AcOH), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate Tartrate, diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- ( 4-chlorophenyl) -α-methyl-5-benzoxazo Ruacetate acetate, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzeneacetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f ) Thiepin-2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4 -(2-Oxocyclopentyl-methyl) phenyl] propioner Acetate, diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzeneacetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate Tartrate, diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy- 2-furanpropionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H- Inden-1-ka Ruboxylate acetate, naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen , Thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac solubility in water> 450 mg,> 400 mg,> 450 mg,> 450 mg,> 350 mg,> 450 mg,> 400 mg,> 450 mg,> 400 mg,> 450 mg,> 350 mg,> 400 mg,> 350 mg,> 400 mg,> 350 mg,> 400 mg ,> 400 mg,> 350 mg,> 450 mg,> 350 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg 0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0 .1 mg, <0.1 mg, <0.1 mg, <0.1 mg, <0.1 mg, and <0.1 mg / ml. In many instances, the slowest or rate limiting step in the series is drug dissolution.

Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, Pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds have very low solubility in gastric juice. They stay in the gastrointestinal tract for a long time and can thus cause damage to gastric mucosal cells. These novel prodrugs will dissolve immediately in the gastric juice when administered orally in dosage forms such as tablets, capsules, solutions, or suspensions. A positive charge on the amino group of these prodrugs will combine with a negative charge on the phosphate head group of the membrane. Thus, the local concentration outside the membrane will be very high, facilitating the passage of these prodrugs from the high concentration region to the low concentration region. As these prodrugs enter the membrane, the hydrophilic moiety will push the prodrug into the cytosol, which is a semi-liquid concentrated aqueous solution or suspension. Due to the short residence in the gastrointestinal tract, prodrugs will not cause damage to gastric mucosal cells. Since the stomach pH is 1-3, the negative charge on the phosphate head group of the membrane is combined with protons (H ⁺ ). The positive charge of the prodrug cannot bind to the negative charge on the phosphate head group of the gastric mucosa. These prodrugs will not cause both primary damage (direct acid damage) and secondary damage (prostaglandin suppression) to the stomach.

  The permeability of aryl- and heteroarylpropionic acids and their positively charged prodrugs and related compounds through human skin was measured in vitro by using modified Franz cells. Modified Franz cells were isolated from human skin tissue (thickness 360-400 μm) in the front and back thighs. The receiving fluid consisted of 10 ml of 2% bovine serum albumin in saline and stirred at 600 rpm. The cumulative amount of these prodrugs and their parent drugs that permeate the skin over time was measured by a specific high performance liquid chromatography method. 30% solution of these prodrugs in 2 mL of pH 7.4 phosphate buffer (0.2 M), or naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid , Flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, cridanac The results obtained using donors consisting of either 30% suspension are shown in FIG. 1, FIG. 2, FIG. 3, or FIG.

Diffusion through human skin, diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (P-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H- Carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5 -Benzoxazole acetate Acid salt, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3 -Chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) Thiepin-2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate, di Tylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetic acid Salt, diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2- Furanpropionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene- 1-carboxyler Acetate, naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, 3.5 mg, 3.0 mg, 4.0 mg, 3.5 mg, 4.0 mg, 3.8 mg for thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, and clidanac , 4.0 mg, 3.5 mg, 4.2 mg, 3.5 mg, 3.7 mg, 4.1 mg, 3.4 mg, 4.2 mg, 3.8 mg, 4.0 mg, 3.6 mg, 4.1 mg, 3.8 mg, 4.0 mg, 0.03 mg, 0.03 mg, 0.03 mg, 0.03 mg, 0.04 mg, 0.03 mg, 0.04 mg, 0.03 mg, 0.03 mg, 0.03 mg, 0.03 mg, 0.04 mg, 0.03 mg, 0.03 mg, 0.04 mg, 0.03 mg, 0.04 mg, 0.03 mg, 0.03 mg, It was calculated apparent velocity value of beauty 0.04 mg / cm ² / h.

  The results are shown as follows: prodrug, diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (P-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H- Carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5 -Benzoxazole acetate vinegar Salt, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3- Chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepine 2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- ( 2-oxocyclopentyl-methyl) phenyl] propionate acetate, die Ruaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate, Diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpro Pionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, or diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1 -Carboxilla Toacetate is naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminopro It diffuses through human skin 100-130 times faster than phen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac. The results show that the positive charge on the dialkylaminoethyl group has a very important role in the drug passing across the membrane and skin barrier. Other prodrugs represented by formula (1) or formula (2) have very high permeability, very close to that of diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate doing.

The in vivo permeability of aryl- and heteroarylpropionic acids and their positively charged prodrugs and related compounds through the skin of untreated hairless mice was compared. A donor consisting of a 20% solution of these compounds in 1 mL of isopropanol was applied to 10 cm ² of the back of a hairless mouse. Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, Plasma levels of pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac were measured by specific high performance liquid chromatography.

  The results (FIGS. 5, 6, 7, and 8) were obtained from diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate. Tartrate, diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- ( 4-chlorophenyl) -α-methyl-5-benzoxazole Cetrate acetate, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3-Chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f ) Thiepin-2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4 -(2-Oxocyclopentyl-methyl) phenyl] propionate Acid salt, diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate Tartrate, diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy- 2-furanpropionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H- Inden-1-cal Peak levels of Kishirato acetate, after application of the donor system, indicating that reached in 50 minutes. Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, When oral administration of pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, it takes 2-4 hours to reach peak plasma levels.

  Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, The peak plasma levels of pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac are ~ 0.01 mg / ml and diethylaminoethyl 2- (6-methoxy-2- Naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (p-chlorobenzoyl)- 5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate Diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate acetate , Diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3-chloro -4- (2,5-dihydro-1 -Pyrrol-1-yl) -α-methylbenzeneacetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate, diethylaminoethyl 2 -(8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate , Diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetic acid Salt, diethylaminoethyl 4,5-diphenyl-2 Oxazole propionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate, diethylaminoethyl 5-benzoyl The peak plasma level of -2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, or diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate is ˜2 mg / ml (almost 200-fold difference). ~ 2 mg / ml naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen in plasma Aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac for producing effective analgesic activity and effective anti-inflammatory activity 20 to 100 times higher than plasma levels. This is a very exciting result. By administering these prodrugs transdermally to patients, therapeutically effective plasma levels of naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen , Carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac It will be very easy and quick. These results indicate that prodrugs can be administered not only orally but also transdermally for various drug treatments. The permeability of other prodrugs represented by formula (1) or formula (2) in vivo is similar to the permeability of diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate. Yes.

  To examine gastroduodenal hemorrhage caused by these prodrugs, rats were given 50 mg / kg of diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- ( 2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) ) Propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetic acid Salt, diethyla Noethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate acetate, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylamino Ethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) Oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-Oxocyclopentyl-methyl) phenyl] propionate acetate, diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate Acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate, diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate Salt, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6 Chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate, naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, 21 flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac Orally administered for days.

  Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, In groups administered pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, there is an average 1-4 mg of stool blood per gram of stool, diethylaminoethyl 2- (6 -Methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (p- Chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2 -Acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole Acetate acetate, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylamino Ethyl 3-chloro-4- ( , 5-Dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate Acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) ) Phenyl] propionate acetate, diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzeneacetate acetate, diethylaminoethyl α, 3-dichloro-4 -Cyclohexylbenzene acetate acetate, diethylaminoethyl 4 5-diphenyl-2-oxazole propionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate Diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate It was found that there was no stool blood in the group that was administered.

The acute toxicity of prodrugs was investigated. Oral diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl 6-chloro-α- in mice Methyl-9H-carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α -Methyl-5-benzoxazole acetate acetate, diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α- Methyl-4-[(2-methyl-2-propenyl) ) Amino] benzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate The LD ₅₀ of acetate is 2.2 g / kg, 0.8 g / kg, 0.7 g / kg, 0.75 g / kg, 1.3 g / kg, 3.5 g / kg, 1.1 g / kg, 0.6 g / kg, 0.2 g / kg. The results show that the prodrugs are their parent drugs, naproxen (LD ₅₀ = 1.234 g / kg), suprofen (LD ₅₀ = 0.59 g / kg), carprofen (LD ₅₀ = 400 mg / kg), pranoprofen (447 mg / kg), benoxaprofen _{(LD 50 = 0.8 g / kg} ), alminoprofen _{(LD 50 = 2400 mg / kg} ), indoprofen _{(LD 50 = 0.7 mg / kg} ), fenclorac (LD ₅₀ = 0.43 g / kg), indicating that it is less toxic than clidanac (LD ₅₀ = 0.035 g / kg).

  Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, Pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac exhibit anti-inflammatory, analgesic, antipyretic, and antirheumatic activities. A good prodrug should return to the parent drug in plasma. The diethylaminoethyl ester group of these prodrugs is rapidly cleaved by human plasma enzymes in vitro, and over 90% of the prodrug is converted back to their parent drug. Prodrugs have a much higher absorption rate and will have a stronger effect than their parent drugs at the same dose. The analgesic, antipyretic and anti-inflammatory activities of these prodrugs were compared with naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen as controls , Pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac.

  Analgesic activity: The pain threshold extension time of the mouse tail was measured according to the D'Amour-Smith method (J. Pharmacol. Exp. Ther., 72, 74 (1941)). After 50 mg / kg of these prodrugs were transdermally administered, the tail of the mouse was exposed to heat, and the pain threshold extension time was measured. The obtained results are shown in FIG. 9, FIG. 10, FIG. 11, and FIG. Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (p-chlorobenzoyl)- 5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate Diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate acetate Diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzeneacetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiopheneacetate acetate, diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl ) Propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-oxocyclopentyl) -Methyl) phenyl] propionate acetate, diethylaminoethyl 4- (1 3-Dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate, diethylaminoethyl 4,5- Diphenyl-2-oxazole propionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate, diethylamino Ethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate acetate Well analgesic activity It was.

  The number of writhing that occurred when the acetic acid solution was administered intraperitoneally to the mice was counted to calculate the inhibition rate based on the control group. Diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (100 mg / kg, B), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (100 mg / kg, C) , Diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (100 mg / kg, D), diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetic acid Salt (100 mg / kg, E), diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate (100 mg / kg, F), diethylaminoethyl α-methyl-5H- [1] benzopyrano [2 , 3-b] pyridine-7-acetate acetate (100 mg / kg, G), diethylaminoethyl 2- (4-chlorophenol) Nenyl) -α-methyl-5-benzoxazole acetate acetate (100 mg / kg, H), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate (100 mg / kg, I), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate (100 mg / kg, J), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrole- 1-yl) -α-methylbenzene acetate acetate (100 mg / kg, K), diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetate (100 mg / kg, L), diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) pro Onate acetate (100 mg / kg, M), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (100 mg / kg, N), diethylaminoethyl 4- (1,3-dihydro- 1-oxo-2H-isoindol-2-yl) -α-methylbenzeneacetate acetate (100 mg / kg, O), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate acetate (100 mg / kg , P), diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (100 mg / kg, Q), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (100 mg / kg, R), Diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetate (100 mg / kg S), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (100 mg / kg, T), diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H Indene-1-carboxylate acetate (100 mg / kg, U) was administered transdermally to mice 30 minutes before the administration of acetic acid solution. Group A is a control group. The results are shown in Table 1.

本結果は、プロドラッグは優れた鎮痛活性を表すということを示す。式（１）又は式（２）で表される他の化合物は類似した鎮痛活性を示す。 Table 1. Rising inhibition rate by prodrugs of aryl- and heteroarylpropionic acids

This result indicates that the prodrug exhibits excellent analgesic activity. Other compounds represented by formula (1) or formula (2) exhibit similar analgesic activity.

  Antipyretic activity: Rats received a sterile E. coli suspension as a pyrogen. The control group is group A. After 2 hours, diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (100 mg / kg, B), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (100 mg / kg kg, C), diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (100 mg / kg, D), diethylaminoethyl 2- (2-fluoro-4-) Biphenylyl) propionate acetate (100 mg / kg, E), diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate (100 mg / kg, F), diethylaminoethyl α-methyl-5H- [1 ] Benzopyrano [2,3-b] pyridine-7-acetate acetate (100 mg / kg, G), diethylaminoethyl 2- (4 -Chlorophenyl) -α-methyl-5-benzoxazole acetate acetate (100 mg / kg, H), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate ( 100 mg / kg, I), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate (100 mg / kg, J), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrole -1-yl) -α-methylbenzene acetate acetate (100 mg / kg, K), diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate acetic acid Salt (100 mg / kg, L), diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2- Yl) propionate acetate (100 mg / kg, M), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (100 mg / kg, N), diethylaminoethyl 4- (1,3- Dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate (100 mg / kg, O), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetate (100 mg / kg, P), diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (100 mg / kg, Q), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (100 mg / kg, R) ), Diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate acetic acid Salt (100 mg / kg, S), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (100 mg / kg, T), diethylaminoethyl 6-chloro-5-cyclohexyl-2 , 3-Dihydro-1H-indene-1-carboxylate acetate (100 mg / kg, U) was administered transdermally. Rat body temperature was measured at 90 minute intervals before and after administration of the test compound. The results are shown in Table 2.

本結果から、プロドラッグは１００ｍｇ／ｋｇ用量において強い解熱活性を示したということが分かる。式（１）及び式（２）で表される他の化合物は類似した解熱活性を示す。 Table 2. Antipyretic activity of prodrugs of aryl- and heteroarylpropionic acids

This result shows that the prodrug showed strong antipyretic activity at a dose of 100 mg / kg. Other compounds represented by formula (1) and formula (2) exhibit similar antipyretic activity.

  Anti-inflammatory activity: diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate (100 mg / kg, B), diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate (100 mg / kg) kg, C), diethylaminoethyl α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate (100 mg / kg, D), diethylaminoethyl 2- (2-fluoro-4-) Biphenylyl) propionate acetate (100 mg / kg, E), diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate (100 mg / kg, F), diethylaminoethyl α-methyl-5H- [1 ] Benzopyrano [2,3-b] pyridine-7-acetate acetate (100 mg / kg, G), diethylaminoethyl 2- ( 4-Chlorophenyl) -α-methyl-5-benzoxazole acetate acetate (100 mg / kg, H), diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate (100 mg / kg, I), diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate (100 mg / kg, J), diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H- Pyrrol-1-yl) -α-methylbenzeneacetate acetate (100 mg / kg, K), diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate Acetate (100 mg / kg, L), diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2 -Yl) propionate acetate (100 mg / kg, M), diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate (100 mg / kg, N), diethylaminoethyl 4- (1,3 -Dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzeneacetate acetate (100 mg / kg, O), diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzeneacetate acetate ( 100 mg / kg, P), diethylaminoethyl 4,5-diphenyl-2-oxazole propionate acetate (100 mg / kg, Q), diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate (100 mg / kg, R), diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate vinegar Acid salt (100 mg / kg, S), diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate (100 mg / kg, T), diethylaminoethyl 6-chloro-5-cyclohexyl- 2,3-Dihydro-1H-indene-1-carboxylate acetate (100 mg / kg, U) was administered transdermally. Group A is a control group. After 60 minutes, the carrageenan solution was administered subcutaneously to the soles of the rats. The volume of the hind paw was measured every hour after the administration of carrageenan, and the rate of increase in the paw volume was calculated and referred to as rate of swelling (%). The obtained results are shown in FIG. 13, FIG. 14, FIG. 15, and FIG. This result indicates that these prodrugs by transdermal administration exhibited good anti-inflammatory activity. Other compounds represented by formula (1) or formula (2) show similar anti-inflammatory activity.

Some oral high doses of NSAIA are also known to exhibit anti-reactive-anti-asthmatic activity due to inhibition of cyclooxygenase activity. These prodrugs have very high membrane permeability and can be used to treat asthma by spraying into the patient's mouth or nose.
These prodrugs can also be used to treat psoriasis, acne, sunburn or other skin diseases because they are anti-inflammatory and have very high membrane permeability.

  The present invention typically includes, in addition to adjuvants and excipients, for example, in the form of tablets, capsules or solutions for oral administration, and solutions, lotions, ointments, emulsions or for transdermal administration. The present invention relates to a drug preparation containing a prodrug represented by formula (1) or formula (2) in the form of a gel. The novel active compounds of formula (1) or formula (2) are used for treating vitamins such as A, B, C, E or beta-carotene in humans or animals to treat NSAIA-treatable conditions. Or in combination with other drugs such as folic acid.

  A transdermal therapeutic application system comprising a compound represented by formula (1) or formula (2) or a composition containing at least a compound represented by formula (1) or formula (2) as an active ingredient is disclosed in humans or animals. NSAIA—can be used to treat a treatable condition. These systems can be dressings or patches consisting of an active substance-containing matrix layer and an impermeable support layer. The most preferred system is an active substance reservoir, which has a permeable bottom surface facing the skin. By controlling the rate of release, this system allows NSAIA to continually reach optimal therapeutic blood levels, increase efficacy, and reduce NSAIA side effects. These systems can be worn anywhere on the wrist, ankle, arm, foot, or body.

式（３）及び式（４）中、Ｘはハロゲン、アルコキシカルボニル又は置換アリールオキシカルボニルオキシを表し、Ａｒｙｌ、Ｒ、Ｙ、Ｚ又はＷは式（１）若しくは式（２）に記載されるものと同じ基を表し、これは式（５）で表される化合物と反応する。

式中、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ又はＮＨを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……である。 The compounds of formula (1) or formula (2) above can be prepared from functional derivatives of aryl- and heteroarylpropionic acids. For example, it is an acid halide or mixed acid anhydride represented by Formula (3) and Formula (4).

In formula (3) and formula (4), X represents halogen, alkoxycarbonyl or substituted aryloxycarbonyloxy, and Aryl, R, Y, Z, or W is described in formula (1) or formula (2) Represents the same group, which reacts with the compound represented by formula (5).

Wherein R ₃ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₄ has H, 1 to 12 carbon atoms. Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, X represents O, S or NH, and n = 0, 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10...

  The compound represented by the above formula (1) or formula (2) is naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, Cups from carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, kuridanak, and related compounds Ring reagents such as N, N′-dicyclohexylcarbodiimide, N, N′-diisopropylcarbodiimide, O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium tetrafluoro Lato, O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate, benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophos It can be prepared by reaction with a compound represented by the formula (5) by using a fert or the like.

式中、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｚはハロゲン、又はｐ−トルエンスルホニルを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５……である。 When X represents O, the compound represented by the above formula (1) or formula (2) is naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3- Acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac And a metal salt or an organic base salt of a related compound, and can be prepared by reaction with a compound represented by the formula (6).

Wherein R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, and R ₄ is H, any one of an alkyl, alkyloxy, alkenyl or alkynyl residue having 1 to 12 carbon atoms. , Or an aryl residue, Z represents halogen or p-toluenesulfonyl, A ⁻ represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or an anion, n = 0, 1, 2, 3, 4, 5.

式中、Ｐは交差結合樹脂を表し、Ａｒｙｌは式（１）及び式（２）に記載されるアリール−及びヘテロアリール基を表し、Ｂは塩基、例えば、ピリジン、ピペリジン、トリエチルアミン、又は他の塩基を表す。これは式（６）で表される化合物と反応する。 When X represents O, the compound represented by the above formula (1) or (2) is represented by the formula (7): naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5 -Methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, It can be prepared from immobilized base salts of oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds.

Where P represents a cross-linked resin, Aryl represents the aryl- and heteroaryl groups described in Formula (1) and Formula (2), B is a base such as pyridine, piperidine, triethylamine, or other Represents a base. This reacts with the compound represented by formula (6).

  Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, Pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related prodrugs of lipophilic and hydrophilic moieties (protonated at physiological pH) Amine groups present in the form of The positively charged amino group of these prodrugs has two excellent advantages. First, it greatly increases the solubility of the drug. When these novel prodrugs are administered orally in dosage forms such as tablets, capsules, solutions or suspensions, they will immediately dissolve in the gastric juice. Second, the positive charge on the amino group of these prodrugs will combine with the negative charge on the phosphate head group of the membrane. Thus, the local concentration outside the membrane will be very high, facilitating the passage of these prodrugs from the high concentration region to the low concentration region. As these prodrugs enter the membrane, the hydrophilic moiety will push the prodrug into the cytosol, which is a semi-liquid concentrated aqueous solution or suspension. Due to the short residence in the gastrointestinal tract, prodrugs will not cause damage to gastric mucosal cells. Experimental results indicate that over 90% of the prodrug has changed back into the drug itself.

  Prodrugs have a much higher absorption rate, and therefore prodrugs can be administered at the same doses of naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, Prophen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds Will have a stronger effect. The experimental results were as follows: prodrug, diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate, diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate, diethylaminoethyl α-methyl- (P-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetate acetate, diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate, diethylaminoethyl 6-chloro-α-methyl-9H- Carbazole-2-acetate acetate, diethylaminoethyl α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetate acetate, diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5 -Benzoxazole acetate Acid salt, diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate acetate, diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate acetate, diethylaminoethyl 3 -Chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate acetate, diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) Thiepin-2-yl) propionate acetate, diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate acetate, diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate acetate, di Tylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate acetate, diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate acetic acid Salt, diethylaminoethyl 4,5-diphenyl-2-oxazolepropionate acetate, diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate acetate, diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2- Furanpropionate acetate, diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate acetate, diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene- 1-carboxyler Acetate is naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen It diffuses through human skin 100-130 times faster than thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac, and related compounds It shows that.

  Naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, When pirprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac, and related compounds, it takes 2-4 hours to reach peak plasma levels However, it took only about 40-50 minutes for these prodrugs to reach peak plasma levels. The most exciting result is that prodrugs can be administered transdermally for various types of drug treatments as well as oral administration, and naproxen, suprofen, α-methyl- (p-chlorobenzoyl)- 5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac , Oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac, and most of the related compounds, most notably gastrointestinal disorders, such as dyspepsia, gastroduodenal bleeding, gastric ulcers, gastritis, and nephrotoxicity This It is. Another major advantage in transdermal administration of these prodrugs is that drug administration will be easier, especially for children.

Preparation of diethylaminoethyl 2- (6-methoxy-2-naphthyl) propionate acetate 11.7 g (0.1 mol) of diethylaminoethanol was dissolved in 10% sodium bicarbonate (200 ml) and acetone (100 ml). 2-4.9 g (0.1 mol) of 2- (6-methoxy-2-naphthyl) propionyl chloride was added to the reaction mixture. The mixture is stirred at room temperature for 3 hours. Evaporate the solvent. The residue is suspended in ethyl acetate (500 ml). 5% sodium bicarbonate (200 ml) is added to the reaction mixture with stirring. The ethyl acetate layer is collected and washed with water (3 × 500 ml). The resulting ethyl acetate solution was dried over anhydrous sodium sulfate. Sodium sulfate is removed by filtration. 6 g of acetic acid is added to the reaction mixture with stirring. The organic solution was evaporated. After drying, 36 g (89.9%) of the desired product is obtained. Hygroscopic product, solubility in water: 350 mg / ml, elemental analysis: C ₂₂ H ₃₁ NO ₅ , molecular weight: 389.49, calculated% C: 67.84; H: 8.02; N: 3.60; O: 20.54, measured% C : 67.82; H: 8.04; N: 3.58; O: 20.56, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.36 (t, 6H), 1.50 (d, 3H), 2.11 (s, 3H), 3.20 (m, 4H), 3.47 (m, 2H), 3.70 (s, 3H), 3.78 (m, 1H), 4.48 (t, 2H), 6.88 (b, 1H), 6.98 (s, 1H), 7.03 (d, 1H), 7.18 (d, 1H), 7.43 (s, 1H), 7.50 (d, 1H), 7.54 (d, 1H).

Preparation of diethylaminoethyl α-methyl-4- (2-thienylcarbonyl) benzeneacetate acetate 28.1 g (0.1 mol) of α-methyl-4- (2-thienylcarbonyl) benzeneacetyl chloride was dissolved in 100 ml of chloroform. . The mixture was cooled to 0 ° C. 15 ml of triethylamine and 11.7 g (0.1 mol) of diethylaminoethanol were added to the reaction mixture. The mixture is stirred at room temperature for 3 hours. Evaporate the solvent. The residue is dissolved in methanol (300 ml) and 5% sodium bicarbonate (200 ml) is added to the reaction mixture. The mixture is stirred for 3 hours. The mixture is evaporated to dryness. Methanol (300 ml) is added to the residue with stirring. The solid is removed by filtration and washed with methanol. The solution is evaporated to dryness and the residue is dissolved in chloroform (200 ml). 6 g of acetic acid is added to the reaction mixture with stirring. Some solids are removed by filtration. Another 6 g of acetic acid is added to the reaction mixture with stirring. The organic solution was evaporated. After drying, 35 g (83.2%) of the desired product are obtained. Hygroscopic product, solubility in water: 400 mg / ml, elemental analysis: C ₂₂ H ₃₁ NO ₅ S, molecular weight: 419.53, calculated% C: 62.68; H: 7.41; N: 3.32; O: 18.98; S: 7.61, found% C: 62.63; H: 7.45; N: 3.31; O: 19.01; S: 7.60, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.36 (t, 6H), 1.45 (d, 3H ), 2.11 (s, 3H), 3.20 (m, 4H), 3.47 (m, 2H), 3.78 (m, 1H), 4.48 (t, 2H), 6.88 (b, 1H), 6.98 (s, 1H) , 7.31 (d, 2H), 7.05 (m, 1H), 7.43 (m, 2H), 7.70 (d, 2H).

Preparation of S-diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate acetate 13.2 g (0.1 mol) of diethylaminoethyl mercaptan was dissolved in 10% sodium bicarbonate (200 ml) and acetone (100 ml). 26.3 g (0.1 mol) of 2- (2-fluoro-4-biphenylyl) propionyl chloride was added to the reaction mixture. The mixture is stirred at room temperature for 3 hours. Evaporate the solvent. The residue is suspended in ethyl acetate (500 ml). 5% sodium bicarbonate (200 ml) is added to the reaction mixture with stirring. The ethyl acetate layer is collected and washed with water (3 × 500 ml). The resulting ethyl acetate solution was dried over anhydrous sodium sulfate. Sodium sulfate is removed by filtration. 6 g of acetic acid is added to the reaction mixture with stirring. The organic solution was evaporated. After drying, 36 g (85.8%) of the desired product is obtained. Hygroscopic product, solubility in water: 400 mg / ml, elemental analysis: C ₂₃ H ₃₀ FNO ₃ S, molecular weight: 419.55, calculated% C: 65.84; H: 7.21; F: 4.53; N: 3.34; O: 11.44; S: 7.64,% observed C: 65.80; H: 7.23; F: 4.55; N: 3.32, O: 11.47; S: 7.63, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.35 (t, 6H), 1.44 (d, 3H), 2.11 (s, 3H), 3.20 (m, 4H), 3.30 (t, 2H), 3.80 (m, 1H), 3.88 (t, 2H), 6.88 (b, 1H ), 6.88 (m, 1H), 6.95 (m, 1H), 7.22 (m, 1H), 7.32 (m, 2H), 7.41 (m, 1H), 7.48 (m, 2H).

Preparation of N-diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylamidoacetate 11.6 g (0.1 mol) diethylaminoethylamine in 10% sodium bicarbonate (200 ml) and acetone (100 ml) Dissolved in. 27.4 g (0.1 mol) of 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylyl chloride was added to the reaction mixture. The mixture is stirred at room temperature for 3 hours. Evaporate the solvent. The residue is suspended in ethyl acetate (500 ml). 5% sodium bicarbonate (200 ml) is added to the reaction mixture with stirring. The ethyl acetate layer is collected and washed with water (3 × 500 ml). The resulting ethyl acetate solution was dried over anhydrous sodium sulfate. Sodium sulfate is removed by filtration. 6 g of acetic acid is added to the reaction mixture with stirring. The organic solution was evaporated. After drying, 35 g (84.8%) of the desired product was obtained. Hygroscopic product, solubility in water: 400 mg / ml, elemental analysis: C ₂₃ H ₃₁ N ₃ O ₄ , molecular weight: 412.50, calculated% C: 66.81; H: 7.56; N: 10.16; O: 15.48, measured % C: 66.90; H: 7.38; N: 10.18; O: 15.54, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.39 (t, 6H), 2.10 (s, 3H), 2.27 (m, 2H ), 3.22 (m, 4H), 3.50 (t, 2H), 3.60 (t, 2H), 3.80 (m, 2H), 3.71 (m, 1H), 5.85 (m, 1H), 6.70 (m, 1H) 6.85 (b, 1H), 7.32 (b, 1H), 7.40 (m, 1H), 7.45 (m, 2H), 7.78 (m, 2H).

N- di et preparation chill aminoethyl 4,5-diphenyl-2-oxazole propionamide acetate 4,5-diphenyl-2-oxazole-propionic acid 29.3g of (0.1 mol) was dissolved in acetonitrile 100 ml. 32.1 g O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium tetrafluoroborate and 30 ml triethylamine were added to the reaction mixture. 11.6 g of diethylaminoethylamine was added to the reaction mixture. The mixture was stirred at room temperature for 3 hours. The solvent was evaporated. 250 ml of ethyl acetate was added to the reaction mixture and the mixture was washed with water (3 × 100 ml). The resulting organic solution was dried over anhydrous sodium sulfate. Sodium sulfate was removed by filtration. 6 g of acetic acid was added to the reaction mixture with stirring. Hexane (200 ml) was added. The solid product was collected by filtration. After drying, 40 g (88.6%) of the desired product is obtained. Hygroscopic product, solubility in water: 400 mg / ml, elemental analysis: C ₂₆ H ₃₃ N ₃ O ₄ , molecular weight: 451.56, calculated% C: 69.16; H: 7.37; N: 9.31; O: 14.17, measured % C: 69.11; H: 7.40; N: 9.30; O: 14.19, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.41 (t, 6H), 2.10 (s, 3H), 2.45 (t, 2H ), 2.76 (t, 2H), 3.22 (m, 4H), 3.49 (t, 2H), 3.60 (t, 2H), 6.87 (b, 1H), 7.22 (b, 1H), 7.22 (m, 2H) , 7.32 (m, 4H), 7.47 (m, 4H).

Preparation of diethylaminoethyl 6-chloro-α-methyl-9H-carbazole-2-acetate acetate 60 g of polymer-bound triethylamine (3 mol / g, 100-200 mesh) was suspended in 180 ml of chloroform. 27.4 g (0.1 mol) of 6-chloro-α-methyl-9H-carbazole-2-acetic acid was added to the mixture with stirring. 43 g (0.15 mol) of diethylaminoethyl bromide.HBr was added to the mixture and the mixture was stirred at room temperature for 5 hours. The polymer was removed by filtration and washed with tetrahydrofuran (3 × 50 ml). Sodium acetate 8.2 g (0.1 mol) was added to the reaction mixture with stirring. The mixture was stirred for 2 hours. The solid was removed by filtration and washed with chloroform (3 × 50 ml). The solution was concentrated in vacuo to 100 ml. Then 300 ml of hexane was added to the solution. The solid product was collected by filtration and washed with hexane (3 × 100 ml). After drying, 38 g (87.8%) of the desired product are obtained. Hygroscopic product, solubility in water: 400 mg / ml, elemental analysis: C ₂₃ H ₂₉ ClN ₂ O ₄ , molecular weight: 432.94, calculated% C: 63.81; H: 6.75; Cl: 8.19, N: 6.47; O : 14.78,% observed C: 63.85; H: 6.78; Cl: 8.17; N: 6.44; O: 14.76, ¹ H-NMR (400 MHz, D ₂ O): δ: 1.39 (t, 6H), 1.47 (d, 3H), 2.11 (s, 3H), 3.21 (m, 4H), 3.49 (m, 2H), 3.77 (m, 1H), 4.48 (t, 2H), 6.80 (b, 1H), 6.85 (m, 1H ), 7.10 (m, 1H), 7.05 (m, 1H), 7.26 (m, 1H), 7.34 (m, 1H), 7.50 (m, 1H), 7.52 (m, 1H).

  The prodrugs represented by formula (1) and formula (2) are naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen , Better than pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac, and related compounds ing. These are naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen in humans or animals. , Aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, clidanac, and related compounds-used in the treatment of treatable conditions obtain. They can be used for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, antipyretic and treatment of dysmenorrhea. They can also be prescribed for diabetic neuropathy and acute migraine. These prodrugs have very high membrane permeability and can be used for the treatment of asthma by inhalation to the patient. They are anti-inflammatory and can be used to treat psoriasis, acne, sunburn or other skin diseases.

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、Ａｒｙｌは以下のものを表す。

全てのＲ、Ｒ₁、Ｒ₂、Ｒ₃基はＣ、Ｈ、Ｏ、Ｓ、Ｎ原子を含んでもよく、単結合、二重結合、及び三重結合を有してもよい。ＣＨ₂基はＯ、Ｓ又はＮＨと置換されてもよい。 Examples of aspects of the present invention include the following.
1. A compound represented by the following formula (1).

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, 1 to 12 carbon atoms X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, and A ⁻ represents any one of alkyl, alkyloxy, alkenyl or alkynyl residues having Represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or anion, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. , Ary It represents the following:.

All R, R ₁ , R ₂ , R ₃ groups may contain C, H, O, S, N atoms and may have single, double, and triple bonds. The CH ₂ group may be substituted with O, S or NH.

式中、ＷはＨ、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、ＹはＨを表し、及びＺは以下のものを表す。

又はＷはＨを表し、Ｚ及びＹは共に以下のものを表す。

全てのＲ、Ｒ₁、Ｒ₂、Ｒ₃基はＣ、Ｈ、Ｏ、Ｓ、Ｎ原子を含んでもよく、単結合、二重結合、及び三重結合を有してもよい。ＣＨ₂基はＯ、Ｓ又はＮＨと置換されてもよい。 2. A compound represented by the following formula (2).

In the formula, W represents H, OH, Cl, F, or Br, and R ₁ is H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms Any one of alkyl, alkyloxy, alkenyl or alkynyl residues, or an aryl residue, X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, A ⁻ represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Y represents H And Z represents the following.

Or, W represents H, and Z and Y both represent the following.

All R, R ₁ , R ₂ , R ₃ groups may contain C, H, O, S, N atoms and may have single, double, and triple bonds. The CH ₂ group may be substituted with O, S or NH.

式中、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ又はＮＨを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……である。 3. A method for preparing the compounds represented by formula (1) and formula (2) according to 1 and 2 above, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy- 2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen , Olpanoxin, ketorolac, clidanac, and functional derivatives of related compounds, such as acid halides or mixed anhydrides, are reacted with a compound represented by the following formula (5).

Wherein R ₃ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₄ has H, 1 to 12 carbon atoms. Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, X represents O, S or NH, and n = 0, 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10...

4). A method for preparing the compounds represented by formula (1) and formula (2) according to 1 and 2 above, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy- 2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen Olpanoxin, ketorolac, or clidanac, and related compounds can be coupled to coupling reagents such as N, N′-dicyclohexylcarbodiimide, N, N′-diisopropylcarbodiimide, O- (benzotriazol-1-yl) -N, N, N ', '-Tetramethyluronium tetrafluoroborate, O- (benzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate, benzotriazol-1-yl-oxy- A method of reacting with the compound represented by the above formula (5) by using tris (dimethylamino) phosphonium hexafluorophosphate or the like.

式中、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｚはハロゲン、又はｐ−トルエンスルホニルを表し、Ａ^-はＣｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、シトラート、又は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……である。 5. A method for preparing the compounds represented by formula (1) and formula (2) according to 1 and 2 above, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy- 2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, beoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, fenchlorac, oxaprozin, fenbufen , Olpanoxin, ketorolac, or clidanac, and a metal salt, an organic base salt, or an immobilized base salt of a related compound are reacted with a compound represented by the following formula (6).

Wherein R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, and R ₄ is H, any one of an alkyl, alkyloxy, alkenyl or alkynyl residue having 1 to 12 carbon atoms. , Or an aryl residue, Z represents halogen or p-toluenesulfonyl, A ⁻ represents Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , citrate, or an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.

6). A composition comprising, as an active ingredient, the compound represented by the formula (1) and the formula (2) or the compound represented by at least the formula (1) and the formula (2) according to the above 1 and 2. A compound or composition that can be administered orally or transdermally to treat a NSAIA-treatable condition in a person or animal, said NSAIA-treatable condition being a toothache, headache, and arthritis And other inflammatory pain, including but not limited to fever, cancer, dysmenorrhea, radiation-induced vomiting, diabetic neuropathy, acute migraine, hemophilic arthropathy, bone loss, and sunburn A compound or composition that is not a thing.
7). A method of treating an NSAIA-treatable condition in a human or animal by administering transdermally (in the form of a solution, spray, lotion, ointment, emulsion or gel) to a body part 1 and The therapeutically effective plasma level of the composition represented by the formula (1) and the formula (2) or the composition containing at least the compound represented by the formula (1) or the formula (2) as an active ingredient according to the above 2. A method of delivering.
8). A therapeutically effective amount of the compound represented by the formula (1) and the formula (2), or at least the compound represented by the formula (1) and the formula (2) according to the above 1 and 2 as an active ingredient A method of locally treating pain, such as headache, toothache, muscle pain, and arthritis and other inflammatory pain, in a person or animal, characterized in that the composition is administered to the site of inflammation.

9. A composition comprising, as an active ingredient, the compound represented by the formula (1) and the formula (2) or the compound represented by at least the formula (1) and the formula (2) according to the above 1 and 2. A compound or composition which can be administered transdermally in the form of a solution, spray, lotion, ointment, emulsion or gel to treat psoriasis, acne, sunburn or other skin diseases.
10. A composition comprising, as an active ingredient, the compound represented by the formula (1) or the formula (2) or the compound represented by at least the formula (1) or the formula (2) according to the above 1 and 2. A compound or composition that is administered by spraying through the mouth or nose or other parts of the body to treat asthma.
11. A composition comprising, as an active ingredient, the compound represented by the formula (1) and the formula (2) or the compound represented by at least the formula (1) and the formula (2) according to the above 1 and 2. A compound or composition for the treatment of inflammatory eye diseases, post-corneal eye pain, glaucoma, or inflammatory and / or painful conditions of the ear (otitis) in a human or animal.
12 3. A compound of formula (1) and formula (2), or at least of formula (1) and formula (2), as described in 1 and 2 above, for treating a NSAIA-treatable condition in a human or animal. 2) A transdermal therapeutic application system for a composition comprising a compound represented by 2) as an active ingredient, which may be a bandage or patch comprising an active substance-containing matrix layer and a non-permeable support layer, most preferably an active substance A reservoir, which has a permeable bottom facing the skin, and by controlling the rate of release, allows NSAIA to continually reach optimal therapeutic blood levels, increase efficacy, and reduce the side effects of NSAIA A system characterized in that it can be reduced.

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、Ａｒｙｌは以下のものを表す。

２−２．式（１）中、Ｒ、Ｒ₁、Ｒ₂、又はＲ₃基がＣ、Ｈ、Ｏ、Ｓ、若しくはＮ原子を含むか、又は単結合、二重結合若しくは三重結合を有するか、又はＣＨ₂基がＯ、Ｓ若しくはＮＨと置換されている、上記１−２に記載の化合物。
３−２．前記陰イオンが、Ｃｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、又はシトラートである、上記１−２に記載の化合物。 1-2. A compound represented by the following formula (1).

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, 1 to 12 carbon atoms X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, and A ⁻ represents any one of alkyl, alkyloxy, alkenyl or alkynyl residues having It represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,..., And Aryl represents the following.

2-2. In formula (1), the R, R ₁ , R ₂ , or R ₃ group contains a C, H, O, S, or N atom, or has a single bond, double bond or triple bond, or CH The compound according to 1-2 above, wherein _two groups are substituted with O, S or NH.
3-2. The compound according to the above 1-2, wherein the anion is Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , or citrate.

式中、ＷはＨ、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ、ＮＨ、ＯＣＨ₂ＣＯＯ、ＯＣＨ₂ＣＯＳ、又はＯＣＨ₂ＣＯＮＨを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……であり、ＹはＨを表し、及びＺは以下のものを表す。

又はＷはＨを表し、Ｚ及びＹは共に以下のものを表す。

５−２．式（２）中、Ｒ、Ｒ₁、Ｒ₂、又はＲ₃基がＣ、Ｈ、Ｏ、Ｓ、若しくはＮ原子を含むか、又は単結合、二重結合若しくは三重結合を有するか、又はＣＨ₂基がＯ、Ｓ若しくはＮＨと置換されている、上記４−２に記載の化合物。
６−２．前記陰イオンが、Ｃｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、又はシトラートである、上記４−２に記載の化合物。 4-2. A compound represented by the following formula (2).

In the formula, W represents H, OH, Cl, F, or Br, and R ₁ is H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms X represents O, S, NH, OCH ₂ COO, OCH ₂ COS, or OCH ₂ CONH, and A ⁻ represents negative Represents ions, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10..., Y represents H, and Z represents the following.

Or, W represents H, and Z and Y both represent the following.

5-2. In formula (2), the R, R ₁ , R ₂ , or R ₃ group contains a C, H, O, S, or N atom, or has a single bond, double bond or triple bond, or CH The compound according to 4-2, wherein ₂ groups are substituted with O, S or NH.
6-2. The compound according to 4-2, wherein the anion is Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , or citrate.

式中、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯ、Ｓ又はＮＨを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……である。 7-2. A method for preparing a compound represented by the formula (1) described in the above 1-2 or the formula (2) described in the above 4-2, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, A method of reacting an acid halide or mixed anhydride of fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac with a compound represented by the following formula (5).

Wherein R ₃ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₄ has H, 1 to 12 carbon atoms. Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, X represents O, S or NH, and n = 0, 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10...

8-2. A method for preparing a compound represented by the formula (1) described in the above 1-2 or the formula (2) described in the above 4-2, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, Fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac is converted to N, N′-dicyclohexylcarbodiimide, N, N′-diisopropylcarbodiimide, O- (benzotriazol-1-yl) -N, N, N ′, N ′. -Tetramethyluronium Tet Lafluoroborate, O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate, and benzotriazol-1-yl-oxy-tris (dimethylamino) The method to make it react with the compound represented by Formula (5) of said 7-2 by using the compound selected from the group which consists of phosphonium hexafluorophosphate.

式中、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₄はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｚはハロゲン、又はｐ−トルエンスルホニルを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９、１０……である。 9-2. A method for preparing a compound represented by the formula (1) described in the above 1-2 or the formula (2) described in the above 4-2, wherein naproxen, suprofen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen, indoprofen, A method of reacting a metal salt, organic base salt, or immobilized base salt of fenchlorac, oxaprozin, fenbufen, olpanoxin, ketorolac, or clidanac with a compound represented by the following formula (6).

Wherein R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₃ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, and R ₄ is H, any one of an alkyl, alkyloxy, alkenyl or alkynyl residue having 1 to 12 carbon atoms. , Or an aryl residue, Z represents halogen or p-toluenesulfonyl, A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ...

10-2. In order to treat a NSAIA-treatable condition in humans or animals, the compound represented by the formula (1) described in the above 1-2 or the formula (2) described in the above 4-2 is included as an active ingredient. The pharmaceutical composition characterized by the above-mentioned.
11-2. The pharmaceutical composition according to the above 10-2, which is orally or transdermally administered.
12-2. The NSAIA-treatable condition is toothache, headache, inflammatory pain, fever, cancer, dysmenorrhea, radiation-induced vomiting, diabetic neuropathy, acute migraine, hemophilic arthropathy, bone loss, and The pharmaceutical composition according to the above 10-2, which is selected from the group consisting of sunburn.
13. The pharmaceutical composition according to 10-2, which is transdermally administered to a part of the body in the form of a solution, spray, lotion, ointment, emulsion or gel.

14 Inflammation for locally treating pain in a human or animal comprising a compound represented by formula (1) described in 1-2 or formula (2) described in 4-2 as an active ingredient A pharmaceutical composition which is administered to a site.
15. 15. The pharmaceutical composition according to 14 above, wherein the pain is headache, toothache, muscle pain, or inflammatory pain.
16. A pharmaceutical composition for treating skin diseases, comprising as an active ingredient a compound represented by formula (1) according to 1-2 or formula (2) according to 4-2.
17. 17. The pharmaceutical composition according to 16 above, wherein the skin disease is psoriasis, acne or sunburn.
18. The pharmaceutical composition according to the above 16, which is transdermally administered in the form of a solution, spray, lotion, ointment, emulsion or gel.

19. Administration by spraying through a body part for treating asthma, comprising as an active ingredient a compound represented by formula (1) described in 1-2 above or formula (2) described in 4-2 above The pharmaceutical composition characterized by the above-mentioned.
20. 20. The pharmaceutical composition as described in 19 above, wherein the body part is the mouth or nose.
21. In a human or animal comprising, as an active ingredient, the compound represented by formula (1) according to 1-2 or formula (2) according to 4-2, inflammatory eye disease, eye pain after corneal surgery, A pharmaceutical composition for treating glaucoma or an inflammatory and / or painful condition of the ear.
22. 22. The pharmaceutical composition according to 21 above, wherein the inflammatory and / or painful state of the ear is otitis.

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨを表し、ＸはＯを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０であり、Ａｒｙｌは以下のものを表す。

〔２〕前記陰イオンが、Ｃｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、又はシトラートである、前記〔１〕に記載の化合物。
〔３〕前記〔１〕に記載の式（１）で表される化合物を調製する方法であって、ナプロキセン、α−メチル−（ｐ−クロロベンゾイル）−５−メトキシ−２−メチルインドール ３−酢酸、ベノキサプロフェン、アルミノプロフェン、チアプロフェン酸、ピルプロフェン、ザルトプロフェン、ベルモプロフェン、ロキソプロフェン若しくはフェンクロラクの酸ハロゲン化物又は混合無水物を、次式（５）で表される化合物と反応させる方法。

式中、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、ＸはＯを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０である。
〔４〕前記〔１〕に記載の式（１）で表される化合物を調製する方法であって、ナプロキセン、α−メチル−（ｐ−クロロベンゾイル）−５−メトキシ−２−メチルインドール ３−酢酸、ベノキサプロフェン、アルミノプロフェン、チアプロフェン酸、ピルプロフェン、ザルトプロフェン、ベルモプロフェン、ロキソプロフェン又はフェンクロラクを、Ｎ，Ｎ’−ジシクロヘキシルカルボジイミド、Ｎ，Ｎ’−ジイソプロピルカルボジイミド、Ｏ−（ベンゾトリアゾール−１−イル）−Ｎ，Ｎ，Ｎ’，Ｎ’−テトラメチルウロニウム テトラフルオロボラート、Ｏ−（ベンゾトリアゾール−１−イル）−Ｎ，Ｎ，Ｎ’，Ｎ’−テ
トラメチルウロニウム ヘキサフルオロホスファート及びベンゾトリアゾール−１−イル−オキシ−トリス（ジメチルアミノ）ホスホニウム ヘキサフルオロホスファートからなる群から選択される化合物を使用することにより、前記〔３〕に記載の式（５）で表される化合物と反応させる方法。
〔５〕前記〔１〕記載の式（１）で表される化合物を調製する方法であって、ナプロキセン、α−メチル−（ｐ−クロロベンゾイル）−５−メトキシ−２−メチルインドール ３−酢酸、ベノキサプロフェン、アルミノプロフェン、チアプロフェン酸、ピルプロフェン、ザルトプロフェン、ベルモプロフェン、ロキソプロフェン若しくはフェンクロラクの金属塩、有機塩基塩、又は固定化された塩基塩を、次式（６）で表される化合物と反応させる方法。

式中、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨを表し、Ｚ₁はハロゲン、又はｐ−トルエンスルホニルを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０である。
〔６〕人又は動物において、ＮＳＡＩＡ−治療可能な状態を治療するための経皮投与用医薬組成物であって、活性成分として下式で表される化合物を含む、前記医薬組成物。

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨを表し、ＸはＯを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０であり、Ａｒｙｌは以下のものを表す。

〔７〕前記ＮＳＡＩＡ−治療可能な状態が、疼痛、熱、癌、月経困難症、放射線誘発性嘔吐、糖尿病性神経障害、急性片頭痛、血友病性関節症、骨喪失、皮膚病、炎症性眼疾患、角膜手術後眼痛、緑内障、耳の炎症性及び／又は有痛性状態、並びに日焼けからなる群から選択される、前記〔６〕に記載の医薬組成物。
〔８〕前記疼痛が、頭痛、歯痛、筋肉痛又は炎症性疼痛である、前記〔７〕に記載の医薬組成物。
〔９〕前記皮膚病が、乾癬、アクネ又は日焼けである、前記〔７〕に記載の医薬組成物。
〔１０〕喘息を治療するための経皮投与用医薬組成物であって、活性成分として下式で表される化合物を含み、体の部分を通してスプレーすることにより投与されることを特徴とする、前記医薬組成物。

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨを表し、ＸはＯを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０であり、Ａｒｙｌは以下のものを表す。

〔１１〕前記体の部分が、口又は鼻である、前記〔１０〕に記載の医薬組成物。
〔１２〕前記耳の炎症性及び／又は有痛性状態が、耳炎である、前記〔７〕に記載の医薬組成物。
〔１３〕人又は動物において、ＮＳＡＩＡ−治療可能な状態を治療するための、下式で表される化合物を含むマトリックス層及び非透過性支持層からなることを特徴とする経皮治療応用システム。

式中、ＲはＣＨ₃、ＯＨ、Ｃｌ、Ｆ、又はＢｒを表し、Ｒ₁はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシル、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₂はＨ、１〜１２炭素原子を有するアルキル、アルキルオキシ、アルケニル若しくはアルキニル残基のいずれか一つ、又はアリール残基を表し、Ｒ₃はＨを表し、ＸはＯを表し、Ａ^-は陰イオンを表し、ｎ＝０、１、２、３、４、５、６、７、８、９又は１０であり、Ａｒｙｌは以下のものを表す。

〔１４〕包帯又はパッチである、前記〔１３〕に記載の経皮治療応用システム。
〔１５〕活性物質貯蔵庫であり、皮膚に面する透過性底面を有する、前記〔１３〕に記載の経皮治療応用システム。
〔１６〕溶液、スプレー、ローション、軟膏、エマルジョン又はゲルの形態で経皮投与される、前記〔６〕〜〔９〕及び〔１２〕のいずれか１項記載の医薬組成物。
〔１７〕前記陰イオンが、Ｃｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、又はシトラートである、前記〔６〕〜〔１２〕のいずれか１項記載の医薬組成物。
〔１８〕前記陰イオンが、Ｃｌ^-、Ｂｒ^-、Ｆ^-、Ｉ^-、ＡｃＯ^-、又はシトラートである、前記〔１３〕〜〔１５〕のいずれか１項記載の経皮治療応用システム。 23. A matrix layer comprising a compound represented by formula (1) according to 1-2 above or formula (2) according to 4-2 above for treating a NSAIA-treatable condition in a human or animal, and A transdermal therapeutic application system characterized by comprising a non-permeable support layer.
24. 24. The transdermal therapeutic application system as described in 23 above, which is a bandage or patch.
25. 24. The transdermal therapeutic application system as described in 23 above, which is an active substance reservoir and has a permeable bottom surface facing the skin.
Another aspect of the present invention may be as follows.
A compound represented by the following formula (1).

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, X represents O A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and Aryl represents the following.

[2] The compound according to [1], wherein the anion is Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , or citrate.
[3] A method for preparing a compound represented by the formula (1) according to [1], wherein naproxen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3- A method of reacting an acid halide or mixed anhydride of acetic acid, beoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen or fenchlorac with a compound represented by the following formula (5).

Wherein R ₁ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₂ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, X represents O, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 Or 10.
[4] A method for preparing a compound represented by the formula (1) according to [1], wherein naproxen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3- Acetic acid, benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen or fenchlorac, N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide, O- (benzotriazole-1) -Yl) -N, N, N ', N'-tetramethyluronium tetrafluoroborate, O- (benzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluoro Phosphate and benzotriazol-1-yl-oxy-tris (dimethylamino The use of phosphonium hexafluorophosphate is selected from the group consisting of sulfates compounds, a method of reacting a compound represented by the formula (5) described in the above [3].
[5] A method for preparing a compound represented by the formula (1) according to [1], wherein naproxen, α-methyl- (p-chlorobenzoyl) -5-methoxy-2-methylindole 3-acetic acid , Benoxaprofen, aluminoprofen, thiaprofenic acid, pyrprofen, zaltoprofen, vermoprofen, loxoprofen or metal salt of fenchlorac, organic base salt, or immobilized base salt is represented by the following formula (6) A method of reacting with a compound.

Wherein R ₁ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₂ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, R ₃ represents H, Z ₁ represents halogen or p-toluenesulfonyl, and A ⁻ represents an anion. , N = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[6] A pharmaceutical composition for transdermal administration for treating a NSAIA-treatable condition in humans or animals, comprising the compound represented by the following formula as an active ingredient.

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, X represents O A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and Aryl represents the following.

[7] The NSAIA-treatable condition is pain, fever, cancer, dysmenorrhea, radiation-induced vomiting, diabetic neuropathy, acute migraine, hemophilic arthropathy, bone loss, skin disease, inflammation [6] The pharmaceutical composition according to the above [6], which is selected from the group consisting of sexual eye disease, eye pain after corneal surgery, glaucoma, inflammatory and / or painful condition of the ear, and sunburn.
[8] The pharmaceutical composition according to [7], wherein the pain is headache, toothache, muscle pain or inflammatory pain.
[9] The pharmaceutical composition according to [7], wherein the skin disease is psoriasis, acne, or sunburn.
[10] A pharmaceutical composition for transdermal administration for treating asthma, comprising a compound represented by the following formula as an active ingredient and administered by spraying through a body part: Said pharmaceutical composition.

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, X represents O A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and Aryl represents the following.

[11] The pharmaceutical composition according to [10], wherein the body part is a mouth or a nose.
[12] The pharmaceutical composition according to [7], wherein the inflammatory and / or painful state of the ear is otitis.
[13] A transdermal therapeutic application system comprising a matrix layer containing a compound represented by the following formula and a non-permeable support layer for treating a NSAIA-treatable condition in a human or animal.

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, X represents O A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and Aryl represents the following.

[14] The transdermal therapeutic application system according to [13], which is a bandage or a patch.
[15] The transdermal therapeutic application system according to [13], which is an active substance storage and has a permeable bottom surface facing the skin.
[16] The pharmaceutical composition according to any one of [6] to [9] and [12], which is transdermally administered in the form of a solution, spray, lotion, ointment, emulsion or gel.
[17] The pharmaceutical composition according to any one of [6] to [12], wherein the anion is Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , or citrate.
[18] The transdermal therapeutic application system according to any one of [13] to [15], wherein the anion is Cl ⁻ , Br ⁻ , F ⁻ , I ⁻ , AcO ⁻ , or citrate.

Claims (6)

A compound represented by the following formula (1).

In the formula, R represents CH ₃ , OH, Cl, F, or Br, and R ₁ represents H, any one of an alkyl, alkyloxyl, alkenyl, or alkynyl residue having 1 to 12 carbon atoms, or an aryl residue. R ₂ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, R ₃ represents H, X represents O A ⁻ represents an anion, n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and Aryl represents the following.

A compound selected from:
Diethylaminoethyl 6-chloro -α- methyl -9H- carbazol-2 acetate .HA,
Diethylaminoethyl 2- (4-chlorophenyl) -α-methyl-5-benzoxazole acetate. HA,
Diethylaminoethyl α-methyl-4-[(2-methyl-2-propenyl) amino] benzene acetate. HA,
Diethylaminoethyl 5-benzoyl-α-methyl-2-thiophene acetate.HA, Diethylaminoethyl 3-chloro-4- (2,5-dihydro-1H-pyrrol-1-yl) -α-methylbenzene acetate.HA ,
Diethylaminoethyl 2- (10,11-dihydro-10-oxodibenzo (b, f) thiepin-2-yl) propionate.HA,
Diethylaminoethyl 2- (8-methyl-10,11-dihydro-11-oxodibenz (b, f) oxepin-2-yl) propionate.HA,
Diethylaminoethyl 2- [4- (2-oxocyclopentyl-methyl) phenyl] propionate.HA,
Diethylaminoethyl 4- (1,3-dihydro-1-oxo-2H-isoindol-2-yl) -α-methylbenzene acetate. HA,
Diethylaminoethyl α, 3-dichloro-4-cyclohexylbenzene acetate. HA,
Diethylaminoethyl 4,5-diphenyl-2-oxazole propionate, HA,
Diethylaminoethyl 3- (4-biphenylylcarbonyl) propionate.HA,
Diethylaminoethyl 5- (4-chlorophenyl) -beta-hydroxy-2-furanpropionate. HA,
Diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylate.HA,
S-diethylaminoethyl 2- (2-fluoro-4-biphenylyl) propionate.HA,
N-diethylaminoethyl 5-benzoyl-2,3-dihydro-1H-pyrrolidine-1-carboxylamido.HA,
N-diethylaminoethyl 4,5-diphenyl-2-oxazolepropionamide. HA, and diethylaminoethyl 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylate. HA.
(A represents an anion.) The ^{anions, Cl -, Br -, F} -, I -, AcO -, or represents a citrate compound according to claim 1 or 2. A method for preparing a compound represented by formula (1) according to claim 1, wherein carprofen or indoprofen acid halide or mixed anhydride is reacted with a compound represented by formula (5) How to make.

Wherein R ₁ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₂ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, X represents O, and n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 Or 10.   A method for preparing a compound represented by formula (1) according to claim 1, wherein carprofen or indoprofen is converted to N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide, O- (benzo Triazol-1-yl) -N, N, N ′, N′-tetramethyluronium tetrafluoroborate, O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro By using a compound selected from nium hexafluorophosphate and benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate represented by formula (5) according to claim 4. A method of reacting with a compound. A method for preparing a compound represented by formula (1) according to claim 1, wherein a metal salt, an organic base salt, or an immobilized base salt of carprofen or indoprofen is represented by the following formula (6): Reacting with the compound represented.

Wherein R ₁ represents H, any one of alkyl, alkyloxy, alkenyl or alkynyl residues having 1 to 12 carbon atoms, or an aryl residue, and R ₂ has H, 1 to 12 carbon atoms Represents any one of an alkyl, alkyloxy, alkenyl or alkynyl residue, or an aryl residue, R ₃ represents H, Z ₁ represents halogen or p-toluenesulfonyl, and A ⁻ represents an anion. , N = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Images